Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded down 4.7% during trading on Tuesday . The stock traded as low as $3.38 and last traded at $3.41, with a volume of 171,508 shares. The stock had previously closed at $3.58.

Several analysts have commented on the stock. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Chardan Capital decreased their target price on shares of Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, June 30th. Stifel Nicolaus decreased their target price on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, June 30th. Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $11.95.

The stock has a 50 day moving average of $3.40 and a 200-day moving average of $5.02. The stock’s market capitalization is $70.05 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.10. On average, analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.